Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography.
Catherine G Fitzgerald DickmannAlexander Franklin McDonaldNhi HuynhAngela RigopoulosZhanqi LiuNancy GuoLaura D OsellameMichael A GormanMichael W ParkerHui Kong GanAndrew Mark ScottUwe AckermannIngrid Julienne Georgette BurvenichJonathan M WhitePublished in: Chemical communications (Cambridge, England) (2023)
Bromodomain and extraterminal (BET) proteins, a family of epigenetic regulators, have emerged as important oncology drug targets. BET proteins have not been targeted for molecular imaging of cancer. Here, we report the development of a novel molecule radiolabelled with positron emitting fluorine-18, [ 18 F]BiPET-2, and its in vitro and preclinical evaluation in glioblastoma models.
Keyphrases
- positron emission tomography
- computed tomography
- cancer therapy
- quantum dots
- pet imaging
- pet ct
- papillary thyroid
- dna methylation
- palliative care
- gene expression
- transcription factor
- living cells
- squamous cell
- fluorescent probe
- stem cells
- drug delivery
- squamous cell carcinoma
- amino acid
- adverse drug
- childhood cancer
- binding protein
- mesenchymal stem cells
- small molecule
- single molecule
- light emitting